Therapeutic targeting of RNA splicing catalysis through inhibition of Protein Arginine Methylation
通过抑制蛋白质精氨酸甲基化来治疗 RNA 剪接催化
基本信息
- 批准号:10393007
- 负责人:
- 金额:$ 38.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-15 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAllelesAntisense OligonucleotidesArginineCatalysisCellsChronic Lymphocytic LeukemiaDataDiseaseDrug TargetingDysmyelopoietic SyndromesEvaluationEventGene ExpressionGenesGeneticHealthIn VitroIndividualLeukemic CellMalignant NeoplasmsMediatingMethylationModelingMolecularMutationMyeloid LeukemiaPatientsPharmaceutical PreparationsPharmacologyPhasePhase I Clinical TrialsPhenotypePoint MutationProcessProtein InhibitionProtein SplicingProtein-Arginine N-MethyltransferaseProteinsProteomeRNA SplicingRNA methylationRNA-Binding ProteinsRNA-targeting therapyRefractorySafetySmall Nuclear RibonucleoproteinsSolid NeoplasmSpliceosome Assembly PathwaySpliceosomesTherapeuticTherapeutic EffectUveal MelanomaWorkcancer cellcancer typecell killingclinical developmentcurative treatmentsearly phase clinical trialefficacy evaluationin vivoinhibitorleukemiamRNA Precursormutantmyeloid leukemia cellnovel therapeutic interventionnovel therapeuticspreclinical developmentsmall moleculesnRNP Structural Core Protein
项目摘要
SUMMARY
Mutations in splicing factors (SF) are highly enriched in a variety of cancer types, particularly myelodysplastic
syndromes (MDS), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL), in addition to solid
tumors such as uveal melanoma. Our group has identified that cells bearing SF mutations cannot tolerate
further perturbations to splicing catalysis and, consistent with this, we have identified that spliceosomal mutant
cancer cells are preferentially sensitive to small molecules that disrupt pre-mRNA splicing.
While the above effort has resulted in an ongoing phase I clinical trial of a spliceosome modulatory compound
for patients with refractory myeloid leukemias, we do not currently know the safety or efficacy of pharmacologic
modulation of core spliceosome function. To this end, our group has also recently identified that inhibiting
spliceosomal assembly through inhibition of arginine methylation of Sm proteins provides an alternate means
of therapeutic splicing inhibition. We have identified that inhibiting either symmetric arginine methylation
(mediated by the protein arginine methyltransferase 5 (PRMT5)) or asymmetric dimethyl arginine methylation
(mediated by type I PRMTs (PRMT1, 4, and 6)) reduces splicing fidelity resulting in strong preferential killing of
SF-mutant leukemias over their wildtype counterparts.
Here we aim to determine if in leukemia, SF-mutations portend greater vulnerability to a “second hit” targeting
splicing through inhibition of type I (PRMT1/4/6) and/or type II (PRMT5) PRMTs. In Aim 1 we will define the
therapeutic potential of inhibiting PRMT5, type I PRMTs, and core spliceosome function, alone or together in
leukemia models with or without a SF mutation. In addition, we will understand the consequences of combined
PRMT inhibition on RNA splicing and gene expression relative to inhibiting PRMT5 or Type I PRMTs alone.
In parallel to the above studies, in Aim 2, we will define the molecular basis for the cooperation between PRMT
inhibition and SF mutations, by first determining the methylation substrates of PRMT5 or Type I PRMTs, and
secondly by determining if individual spliceosomal changes mediated by inhibiting PRMTs or core spliceosome
function can be mimicked by anti-sense oligonucleotides, thereby providing an orthogonal novel therapeutic
approach to eliminate SF-mutant cancer cells.
The significance of these studies is that inhibitors of PRMTs are now entering phase I clinical trials in patients
with a variety of cancer types and defining the mechanistic effects and therapeutic utility of PRMT inhibitors for
specific genetic subsets of cancers may have incredible therapeutic importance. The health relatedness is
that our studies may identify new therapeutic opportunities for a variety of cancer types that have no curative
therapies for the majority of patients with these diseases currently.
总结
剪接因子(SF)突变在多种癌症类型中高度富集,特别是骨髓增生异常
在一些实施方案中,除了实体瘤治疗外,还治疗骨髓增生异常综合征(MDS)、急性髓性白血病(AML)和慢性淋巴细胞白血病(CLL)。
肿瘤如葡萄膜黑色素瘤。我们的研究小组已经确定,携带SF突变的细胞不能耐受
进一步干扰剪接催化,与此一致,我们已经确定剪接体突变体,
癌细胞优先对破坏前mRNA剪接的小分子敏感。
虽然上述努力已经导致剪接体调节化合物的正在进行的I期临床试验,
对于难治性髓系白血病患者,我们目前尚不清楚药物治疗的安全性或有效性。
核心剪接体功能的调节。为此,我们的小组最近还确定,
通过抑制Sm蛋白的精氨酸甲基化进行剪接体组装提供了一种替代方法
治疗性剪接抑制我们已经发现,抑制对称精氨酸甲基化
(由蛋白质精氨酸甲基转移酶5(PRMT 5)介导)或不对称二甲基精氨酸甲基化
(由I型PRMT(PRMT 1、4和6)介导)降低剪接保真度,导致对
SF突变型白血病的发病率高于野生型。
在这里,我们的目标是确定在白血病中,SF-突变是否预示着更容易受到“二次打击”的影响。
通过抑制I型(PRMT 1/4/6)和/或II型(PRMT 5)PRMT进行剪接。在目标1中,我们将定义
单独或一起抑制PRMT 5、I型PRMT和核心剪接体功能的治疗潜力,
具有或不具有SF突变的白血病模型。此外,我们将了解合并的后果
相对于单独抑制PRMT 5或I型PRMT,PRMT对RNA剪接和基因表达的抑制。
在上述研究的同时,在目标2中,我们将定义PRMT之间合作的分子基础。
通过首先确定PRMT 5或I型PRMT的甲基化底物,
其次,通过确定是否通过抑制PRMT或核心剪接体介导个体剪接体的变化,
功能可以通过反义寡核苷酸模拟,从而提供正交的新治疗剂,
消除SF突变癌细胞的方法。
这些研究的意义在于PRMT抑制剂现在进入了患者的I期临床试验
与各种癌症类型,并定义PRMT抑制剂的机制作用和治疗效用,
癌症的特定遗传亚群可能具有难以置信的治疗重要性。健康相关性是
我们的研究可能会为各种无法治愈的癌症类型找到新的治疗机会,
目前大多数患有这些疾病的患者的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ernesto Guccione其他文献
Ernesto Guccione的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ernesto Guccione', 18)}}的其他基金
Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients
实施基于 qPCR 的检测方法,对免疫功能低下患者的 SARS-CoV-2 特异性 T 细胞进行定量
- 批准号:
10580531 - 财政年份:2023
- 资助金额:
$ 38.36万 - 项目类别:
FUNCTIONAL CHARACTERIZATION OF NOVEL DETERMINANTS OF HOLOPROSENCEPHALY (HPE)
前脑无裂畸形 (HPE) 的新决定因素的功能特征
- 批准号:
10366059 - 财政年份:2021
- 资助金额:
$ 38.36万 - 项目类别:
Resource Core D - Bioinformatics and Statistical Analysis Core
资源核心 D - 生物信息学和统计分析核心
- 批准号:
10676795 - 财政年份:2021
- 资助金额:
$ 38.36万 - 项目类别:
FUNCTIONAL CHARACTERIZATION OF THE PRDM10-ZN FINGER TRANSCRIPTION FACTOR IN EARLY MAMMALIAN DEVELOPMENT
PRDM10-ZN 指转录因子在早期哺乳动物发育中的功能特征
- 批准号:
10477941 - 财政年份:2021
- 资助金额:
$ 38.36万 - 项目类别:
FUNCTIONAL CHARACTERIZATION OF NOVEL DETERMINANTS OF HOLOPROSENCEPHALY (HPE)
前脑无裂畸形 (HPE) 的新决定因素的功能特征
- 批准号:
10596128 - 财政年份:2021
- 资助金额:
$ 38.36万 - 项目类别:
Resource Core D - Bioinformatics and Statistical Analysis Core
资源核心 D - 生物信息学和统计分析核心
- 批准号:
10463725 - 财政年份:2021
- 资助金额:
$ 38.36万 - 项目类别:
FUNCTIONAL CHARACTERIZATION OF THE PRDM10-ZN FINGER TRANSCRIPTION FACTOR IN EARLY MAMMALIAN DEVELOPMENT
PRDM10-ZN 指转录因子在早期哺乳动物发育中的功能特征
- 批准号:
10617819 - 财政年份:2021
- 资助金额:
$ 38.36万 - 项目类别:
Therapeutic targeting of RNA splicing catalysis through inhibition of Protein Arginine Methylation
通过抑制蛋白质精氨酸甲基化来治疗 RNA 剪接催化
- 批准号:
10165673 - 财政年份:2020
- 资助金额:
$ 38.36万 - 项目类别:
DISSECTING THE ROLE OF PRDM15 IN NORMAL HEMATOPOIESIS AND B-CELL MALIGNANCIES
剖析 PRDM15 在正常造血和 B 细胞恶性肿瘤中的作用
- 批准号:
10316262 - 财政年份:2020
- 资助金额:
$ 38.36万 - 项目类别:
Therapeutic targeting of RNA splicing catalysis through inhibition of Protein Arginine Methylation
通过抑制蛋白质精氨酸甲基化来治疗 RNA 剪接催化
- 批准号:
10703206 - 财政年份:2020
- 资助金额:
$ 38.36万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 38.36万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 38.36万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 38.36万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 38.36万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 38.36万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 38.36万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 38.36万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 38.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 38.36万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 38.36万 - 项目类别:














{{item.name}}会员




